Targeting PRKCSH may have several therapeutic advantages, including reestablishing immune surveillance through M1 reactivation, making tumors more susceptible to apoptosis and ferroptosis, and disrupting stress-adaptive systems that promote tumor survival. This evidence concerns the gene PRKCSH and neoplasm.